EGFR and squamous cell carcinoma: Given the histopathological similarities between KA and squamous cell carcinoma (SCC), therapeutic strategies involving epidermal growth factor receptor (EGFR) inhibitors (e.g., cetuximab) or immune checkpoint inhibitors (e.g., cemiplimab) appear rational [11,12,13].